Home  |  About us  |  Editorial board  |  Ahead of print  | Current issue  |  Archives  |  Submit article  |  Instructions |  Search  |   Subscribe  |  Advertise  |  Contacts  |  Login 
  Users Online: 217Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  

 Table of Contents      
EDITORIAL
Year : 2022  |  Volume : 13  |  Issue : 1  |  Page : 1-2

Clinical trials and Consolidated Standards of Reporting Trials: Continuing concerns of compliance in COVID-19 era


Clinical Research and Drug Development, Mumbai, Maharashtra, India

Date of Submission03-Dec-2021
Date of Acceptance07-Jan-2021
Date of Web Publication06-Jan-2022

Correspondence Address:
Dr. Arun Bhatt
ClinInvent Research Pvt. Ltd. A-302, Everest Chambers, Next to Star TV Office, Marol Naka, Andheri-Kurla Road, Andheri (E), Mumbai - 400 059, Maharashtra
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/picr.picr_259_21

Rights and Permissions

How to cite this article:
Bhatt A. Clinical trials and Consolidated Standards of Reporting Trials: Continuing concerns of compliance in COVID-19 era. Perspect Clin Res 2022;13:1-2

How to cite this URL:
Bhatt A. Clinical trials and Consolidated Standards of Reporting Trials: Continuing concerns of compliance in COVID-19 era. Perspect Clin Res [serial online] 2022 [cited 2022 Jan 26];13:1-2. Available from: https://www.picronline.org/text.asp?2022/13/1/1/335017

COVID-19 global pandemic's serious health consequences created an urgent unmet medical need to discover effective therapies for managing disease and preventing complications. This has led to an exponential increase in clinical research publications related to COVID-19. PubMed lists 202,277 articles. The urgency of planning and the speed of publication have raised major concerns regarding the scientific rigor and quality of clinical research in COVID-19.[1],[2] Jung et al. performed a systematic review to evaluate the methodological quality of 686 COVID-19 articles. Quality scores of methodology in COVID-19 articles were lower as compared to historical controls.[1] However, this study included only three randomized controlled trials (RCTs). PubMed includes 1424 clinical trials, and Clinitrials.gov has registered 1461 RCTs. As RCTs are gold standard for supporting evidence of efficacy of different interventions, it is imperative to assess quality of published RCTs on COVID-19.

The quality of clinical trials could be assessed by reviewing the publications and preprints against Consolidated Standards of Reporting Trials (CONSORT).[3] The CONSORT statement consists of a flow diagram and a checklist of 37 items (25 items + 12 subitems) that guide the reporting of essential items of an RCT. The checklist consists of six sections: (1) title and abstract (one item), (2) introduction (one item), (3) methods (ten items), (4) results (seven items), (5) discussion (three items), and (6) other information (three items). Endorsement of CONSORT by over 600 biomedical journals and prominent editorial organizations such as International Committee of Medical Journal Editors and the World Association of Medical Editors[2],[3] has contributed to improvement in overall reporting quality of RCTs. However, recent studies of quality of published RCTs of COVID-19 interventions appear to reverse this trend.

Yin et al., in a study of evaluation of reporting quality of 53 RCTs in COVID-19 patients, found that the average reporting rate for 37 items in the CONSORT checklist was 53.85%. For the methodological section, the reporting rate was 31.35%.[2] For some critical items – trial design, sample size, allocation concealment, randomization implementation, blinding, ancillary analyses, and protocol – the reporting rate was very low <20%. Only a small number –7 studies (13.21%) reported method of masking concealment, while 9 studies (16.98%) reported the details of blinding.[2] The authors also assessed adherence to CONSORT scoring for each item and subitem and reported a mean overall adherence score of 13.02 ± 3.546 (range 7–22). Gaps in reporting quality of clinical trials are not unique to COVID-19 trials.

In this issue of Journal, Gupta et al. have reported an appraisal of RCTs published in Indian Journal of Pharmacology (IJP).[4] The authors screened 1102 articles published in IJP between 2011 and 2016 and selected 28 RCTs with full-text articles for analysis. They evaluated the quality of these articles against a checklist based on the CONSORT 2010 guidelines for reporting parallel group randomized trials. Deficiencies in the reporting of methods were (1) no description of sample size determination in 7 (25%); (2) mechanism to implement the random allocation sequence not reported in 8 (64.29%) articles; and (3) details of blinding process not available in 12 (42.86%). In the “Results” section, the deficiencies were (1) not reporting precision of effect size in 22 (78.57 %); (2) no participant flow diagram and “intention-to-treat” analysis in 18 (64.29%) articles; and (3) no data on baseline demographics in 8 (28.57%). Trial limitations were not discussed in 9 (32.14%) articles. Another significant omission was no registration of RCT in 19 (67.86%) articles.

Suboptimal adherence to reporting guidelines remains a concern among the clinical research community. In a 2018 systematic review, Jin et al. analyzed whether reporting of medical research adheres to well-known reporting guidelines.[5] They included reviews published over 20 years – between January 1996 and September 2016 – which assessed compliance to reporting standards for clinical trials, systematic reviews, observational studies, meta-analysis, diagnostic accuracy, economic evaluations, and preclinical animal studies.[5] Of the 124 studies assessed, overall adherence to any reporting standards was suboptimal in 87.9%. Compliance to the CONSORT statement was suboptimal in 71 (88%) of 81 RCTS examined.[5]

Several factors related to (1) ethical aspects, (2) authorship, (3) study, and (4) journal were associated with improved adherence to reporting guidelines.[5]

Ethical factors were: Articles describing details of ethics committee approval, informed consent of participant, and source of funding.[5]

Authorship factors were: The level of expertise of author team in research methods and having multiple authors.[5] Low reporting rates for critical items of methodology, results, and discussion may reflect the lack of relevant knowledge of the authors in clinical research methodology and reporting guidelines such as CONSORT. For original research articles, “Methods” section is the most frequently responsible for rejection of the manuscript.[6] Young clinical researchers should be aware of relevant reporting guidelines – CONSORT while preparing the manuscript.

Study design factors were: Well-designed, adequately powered trials providing detailed study methods.[5] Poor reporting of methodological items, e.g., randomization sequence generation, sample size, allocation concealment, and blinding, could result from a perception that the clinical aspects of RCTs are of greater importance and interest compared to study design issues.[7] Some studies have demonstrated a strong association between poorly reported trials and poorly designed or conducted trials.[7]

Journal factors were: Journals with high impact or endorsing reporting guidelines.[5] Such journals usually request authors to submit a completed CONSORT checklist, which would be instrumental in enhancing the quality of reporting.

Suboptimal quality of reporting of RCT in publications can result in inaccurate conclusions regarding treatment effect. Reporting guidelines such as CONSORT are an essential tool in the endeavor to ensure consistency in reporting of RCTs. The authors, peer reviewers, and editors should make concerted efforts to meet CONSORT standards.

 
   References Top

1.
Jung RG, Di Santo P, Clifford C, Prosperi-Porta G, Skanes S, Hung A, et al. Methodological quality of COVID-19 clinical research. Nat Commun 2021;12:943.  Back to cited text no. 1
    
2.
Yin Y, Shi F, Zhang Y, Zhang X, Ye J, Zhang J. Evaluation of reporting quality of randomized controlled trials in patients with COVID-19 using the CONSORT statement. PLoS One 2021;16:e0257093.  Back to cited text no. 2
    
3.
Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 statement: Updated guidelines for reporting parallel group randomised trials. PLoS Med 7: e1000251. https://doi.org/10.1371/journal.pmed.1000251.  Back to cited text no. 3
    
4.
Gupta SK, Tiwari RK, Goel RK. The critical appraisal of randomized controlled trials published in an Indian journal to assess the quality of reporting: A retrospective, cross-sectional study. Perspect Clin Res 2022;1:33-7.  Back to cited text no. 4
  [Full text]  
5.
Jin Y, Sanger N, Shams I, Luo C, Shahid H, Li G, et al. Does the medical literature remain inadequately described despite having reporting guidelines for 21 years? – A systematic review of reviews: An update. J Multidiscip Healthc 2018;11:495-510.  Back to cited text no. 5
    
6.
Bhatt A. Advice to authors for avoiding flaws in preparation of original research manuscripts. Perspect Clin Res 2021;12:229-33.  Back to cited text no. 6
  [Full text]  
7.
Péron J, Pond GR, Gan HK, Chen EX, Almufti R, Maillet D, et al. Quality of reporting of modern randomized controlled trials in medical oncology: A systematic review. J Natl Cancer Inst 2012;104:982-9.  Back to cited text no. 7
    




 

Top
  
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
    References

 Article Access Statistics
    Viewed434    
    Printed4    
    Emailed0    
    PDF Downloaded71    
    Comments [Add]    

Recommend this journal